<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2026-01-21 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval." When finalized, this guidance will provide recommendations to sponsors about using minimal residual disease (MRD) and complete response (CR) in multiple myeloma as primary endpoints in trials evaluating drug and biological products intended to treat pat...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2026-01068</p>
    <p><strong>Publication Date:</strong> 2026-01-21</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2026/01/21/2026-01068/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support">https://www.federalregister.gov/documents/2026/01/21/2026-01068/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2026-01068</div>
    <p><a href="index.html">‚Üê Back to Breaking News Wire</a></p>
</body>
</html>
